Your cart is currently empty!
Enjoy Free Shipping on all Orders of $200 or more. USE CODE: MERRY24 for 25% OFF all Reg. Priced Products
*Earn up to $50 off for every new customer Referral!
BPC-157 – 10mg, Premium Lyophilized Peptide Powder, 99% Purity.
BUY MORE & SAVE!
Buy 5 – Get 5% discount
Buy 10 or more – Get 10% discount
Discount will automatically be applied at checkout
*Reference the product tabs below for additional Product Info & Quality Report (COA)
Source | Subject | Reference Title | Citation | More Info | |
---|---|---|---|---|---|
Thymosin Alpha-1 | National Library of Medicine (NIH) | Cancer | A Reappraisal of Thymosin Alpha1 in Cancer Therapy | Costantini C, Bellet MM, Pariano M, Renga G, Stincardini C, Goldstein AL, Garaci E, Romani L. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019 Sep 6;9:873. doi: 10.3389/fonc.2019.00873. PMID: 31555601; PMCID: PMC6742685. | View |
Thymosin Alpha-1 | National Library of Medicine (NIH) | Hepatitis B | Thymosin alpha-1 treatment in chronic hepatitis B | Wu X, Jia J, You H. Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opin Biol Ther. 2015;15 Suppl 1:S129-32. doi: 10.1517/14712598.2015.1007948. Epub 2015 Feb 1. PMID: 25640173. | View |
Thymosin Alpha-1 | National Library of Medicine (NIH) | Cystic Fibrosis | Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis | Bellet MM, Borghi M, Pariano M, Renga G, Stincardini C, D’Onofrio F, Brancorsini S, Garaci E, Costantini C, Romani L. Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis. Eur J Med Chem. 2021 Jan 1;209:112921. doi: 10.1016/j.ejmech.2020.112921. Epub 2020 Oct 9. PMID: 33071052. | View |
Thymosin Alpha-1 | National Library of Medicine (NIH) | Infectious Disease | Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application | Tao N, Xu X, Ying Y, Hu S, Sun Q, Lv G, Gao J. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules. 2023 Apr 17;28(8):3539. doi: 10.3390/molecules28083539. PMID: 37110771; PMCID: PMC10144173. | View |
Thymosin Alpha-1 | National Library of Medicine (NIH) | Respiratory (COPD) | Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients | Jia Z, Feng Z, Tian R, Wang Q, Wang L. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients. Immunopharmacol Immunotoxicol. 2015;37(4):388-92. doi: 10.3109/08923973.2015.1069837. PMID: 26250523. | View |
Thymosin Alpha-1 | ACS Omega | Cancer (Lung) | Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo | Renhao Peng, Caoying Xu, Heng Zheng, and Xingzhen Lao ACS Omega 2020 5 (18), 10374-10381 DOI: 10.1021/acsomega.0c00220 | View |
Semaglutide | National Library of Medicine (NIH) | Diabetes | Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes | Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022 Jun;23(3):521-539. doi: 10.1007/s11154-021-09699-1. Epub 2022 Jan 7. PMID: 34993760; PMCID: PMC8736331. | View |
Retatrutide | National Library of Medicine (NIH) | Diabetes | Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA | Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. PMID: 37385280. | View |
Semaglutide | National Library of Medicine (NIH) | Weight Loss | Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity | Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022 Sep 1;5(9):e2231982. doi: 10.1001/jamanetworkopen.2022.31982. PMID: 36121652; PMCID: PMC9486455. | View |
Retatrutide | National Library of Medicine (NIH) | Weight Loss | Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence | Naeem M, Imran L, Banatwala UESS. Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. Health Sci Rep. 2024 Feb 5;7(2):e1864. doi: 10.1002/hsr2.1864. PMID: 38323122; PMCID: PMC10844714. | View |
Semaglutide | National Library of Medicine (NIH) | Liver (NAFLD) | Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity | Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther. 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316. Epub 2019 Jun 10. PMID: 31246368; PMCID: PMC6617813. | View |
BPC-157 | National Library of Medicine (NIH) | Healing (Tendon) | The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration | Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011 Mar;110(3):774-80. doi: 10.1152/japplphysiol.00945.2010. Epub 2010 Oct 28. PMID: 21030672. | View |
BPC-157 | National Library of Medicine (NIH) | Arthritis (Knee Pain) | Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain | Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021 Jul;27(4):8-13. PMID: 34324435. | View |
BPC-157 | National Library of Medicine (NIH) | Wound Healing | Stable Gastric Pentadecapeptide BPC 157 and Wound Healing | Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Pavlov KH, Petrovic A, Sikiric S, Vranes H, Prtoric A, Zizek H, Durasin T, Dobric I, Staresinic M, Strbe S, Knezevic M, Sola M, Kokot A, Sever M, Lovric E, Skrtic A, Blagaic AB, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021 Jun 29;12:627533. doi: 10.3389/fphar.2021.627533. PMID: 34267654; PMCID: PMC8275860. | View |
GHK-Cu | National Library of Medicine (NIH) | Multiple (Anti-aging, Healing, Inflammation, Hair Growth) | Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data | Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018 Jul 7;19(7):1987. doi: 10.3390/ijms19071987. PMID: 29986520; PMCID: PMC6073405. | View |
GHK-Cu | National Library of Medicine (NIH) | Hair Regeneration | Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application | Liu T, Liu Y, Zhao X, Zhang L, Wang W, Bai D, Liao Y, Wang Z, Wang M, Zhang J. Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application. Bioact Mater. 2023 Nov 1;32:502-513. doi: 10.1016/j.bioactmat.2023.10.002. PMID: 38026438; PMCID: PMC10643103. | View |
CJC-1295-ND | National Library of Medicine (NIH) | Bone Density (Osteoporosis) | Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial | Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res. 2003 Mar;18(3):393-405. doi: 10.1359/jbmr.2003.18.3.393. PMID: 12619921. | View |
TB-500 | National Library of Medicine (NIH) | Wound Healing | Thymosin beta4 accelerates wound healing | Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999 Sep;113(3):364-8. doi: 10.1046/j.1523-1747.1999.00708.x. PMID: 10469335. | View |
TB-500 | National Library of Medicine (NIH) | Hair Growth | Thymosin beta 4 induces hair growth via stem cell migration and differentiation | Philp D, St-Surin S, Cha HJ, Moon HS, Kleinman HK, Elkin M. Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci. 2007 Sep;1112:95-103. doi: 10.1196/annals.1415.009. PMID: 17947589. | View |
TB-500 | National Library of Medicine (NIH) | Anti-Inflammatory | Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids | Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, Pappin DJ, Stevenson RD. Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med. 1999 Dec;5(12):1424-7. doi: 10.1038/71002. PMID: 10581087. | View |
Tesamorelin | National Library of Medicine (NIH) | Visceral Fat, HIV | Visceral Fat Reduction with Tesamorelin Is Associated with Improved Liver Enzymes in HIV | Fourman LT, Czerwonka N, Feldpausch MN, Weiss J, Mamputu JC, Falutz J, Morin J, Marsolais C, Stanley TL, Grinspoon SK. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017 Oct 23;31(16):2253-2259. doi: 10.1097/QAD.0000000000001614. PMID: 28832410; PMCID: PMC5633509. | View |
Tesamorelin | National Library of Medicine (NIH) | NAFLD | Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial | Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019 Dec;6(12):e821-e830. doi: 10.1016/S2352-3018(19)30338-8. Epub 2019 Oct 11. PMID: 31611038; PMCID: PMC6981288. | View |
Tesamorelin | National Library of Medicine (NIH) | Scarpenia, HIV | The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV | Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405. | View |
TB-500 | National Library of Medicine (NIH) | Regenerative (Healing) | The regenerative peptide thymosin ?4 accelerates the rate of dermal healing in preclinical animal models and in patients | Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin ?4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012 Oct;1270:37-44. doi: 10.1111/j.1749-6632.2012.06717.x. PMID: 23050815. | View |
TB-500 | National Library of Medicine (NIH) | Performance Enhancement | The potential use and abuse of thymosin ?-4 in sport and exercise science | Davison G, Brown S. The potential use and abuse of thymosin ?-4 in sport and exercise science. J Sports Sci. 2013;31(9):917-8. doi: 10.1080/02640414.2013.771958. Epub 2013 Feb 20. PMID: 23421910. | View |
TB-500 | National Library of Medicine (NIH) | Traumatic Brain Injury | Neuroprotective and neurorestorative effects of Thymosin beta 4 treatment following experimental traumatic brain injury | Xiong Y, Mahmood A, Meng Y, Zhang Y, Zhang ZG, Morris DC, Chopp M. Neuroprotective and neurorestorative effects of thymosin ?4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci. 2012 Oct;1270:51-8. doi: 10.1111/j.1749-6632.2012.06683.x. PMID: 23050817; PMCID: PMC3547647. | View |
TB-500 | National Library of Medicine (NIH) | Regenerative (Cardiac) | Thymosin beta4 and cardiac repair | Shrivastava S, Srivastava D, Olson EN, DiMaio JM, Bock-Marquette I. Thymosin beta4 and cardiac repair. Ann N Y Acad Sci. 2010 Apr;1194:87-96. doi: 10.1111/j.1749-6632.2010.05468.x. PMID: 20536454. | View |
TB-500 | National Library of Medicine (NIH) | Liver (NAFLD) | Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease | Jiang Y, Han T, Zhang ZG, Li M, Qi FX, Zhang Y, Ji YL. Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease. Chronic Dis Transl Med. 2017 Jul 8;3(3):165-168. doi: 10.1016/j.cdtm.2017.06.003. PMID: 29063072; PMCID: PMC5643779. | View |
Epithalon | National Library of Medicine (NIH) | Anti-Aging | Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice | Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. doi: 10.1023/a:1025114230714. PMID: 14501183. | View |
Epithalon | National Library of Medicine (NIH) | Cancer (Tumors) | Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice | Kossoy G, Anisimov VN, Ben-Hur H, Kossoy N, Zusman I. Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo. 2006 Mar-Apr;20(2):253-7. PMID: 16634527. | View |
Epithalon | Alzheimers Drug Discovery Foundation | Cognitive, Aging, Cancer | Epithalamin/Epithalon | Alzheimer’s Drug Discovery Foundation. (n.d.). Cognitive vitality reports. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Epithalamin-and-Epithalon-Cognitive-Vitality-For-Researchers.pdf | View |
Epithalon | National Library of Medicine (NIH) | Neuroendocrine Regulation (Melatonin Synthesis – Improved Sleep) | Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys | Khavinson V, Goncharova N, Lapin B. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinol Lett. 2001 Aug;22(4):251-4. PMID: 11524632. | View |
Ipamorelin | National Library of Medicine (NIH) | Growth Hormone | Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats | Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi: 10.1054/ghir.1999.9998. PMID: 10373343. | View |
Ipamorelin | National Library of Medicine (NIH) | Body Composition (Hypogonadal) | Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males | Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996. | View |
Ipamorelin | National Library of Medicine (NIH) | Gastric Emptying (Dysmotility) | Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus | Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012 Oct 19;4:149-55. doi: 10.2147/JEP.S35396. PMID: 27186127; PMCID: PMC4863553. | View |
BPC-157 | National Library of Medicine (NIH) | Hormone Regulation | Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts | Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014 Nov 19;19(11):19066-77. doi: 10.3390/molecules191119066. PMID: 25415472; PMCID: PMC6271067. | View |
BPC-157 | National Library of Medicine (NIH) | Anti-Inflammtory | Antiinflammatory effect of BPC 157 on experimental periodontitis in rats | Keremi B, Lohinai Z, Komora P, Duhaj S, Borsi K, Jobbagy-Ovari G, Kallo K, Szekely AD, Fazekas A, Dobo-Nagy C, Sikiric P, Varga G. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:115-22. PMID: 20388954. | View |
BPC-157 | National Library of Medicine (NIH) | Brain-Gut (GI – Gastrointestinal) | Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications | Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, Grgic T, Strbe S, Zukanovic G, Crvenkovic D, Madzarac G, Rukavina I, Sucic M, Baric M, Starcevic N, Krstonijevic Z, Bencic ML, Filipcic I, Rokotov DS, Vlainic J. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. doi: 10.2174/1570159×13666160502153022. PMID: 27138887; PMCID: PMC5333585. | View |
BPC-157 | National Library of Medicine (NIH) | Central Nervous System (Brain-Gut Axis) | Pentadecapeptide BPC 157 and the central nervous system | Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022 Mar;17(3):482-487. doi: 10.4103/1673-5374.320969. PMID: 34380875; PMCID: PMC8504390. | View |
GHK-Cu | National Library of Medicine (NIH) | Skin Regeneration (Tissue Repair) | GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration | Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi: 10.1155/2015/648108. Epub 2015 Jul 7. PMID: 26236730; PMCID: PMC4508379. | View |
GHK-Cu | National Library of Medicine (NIH) | Anti-Aging | The potential of GHK as an anti-aging peptide | Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020 Mar 27;2(1):58-61. doi: 10.31491/apt.2020.03.014. PMID: 35083444; PMCID: PMC8789089. | View |
GHK-Cu | National Library of Medicine (NIH) | Hair Growth | The effect of tripeptide-copper complex on human hair growth in vitro | Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007 Jul;30(7):834-9. doi: 10.1007/BF02978833. PMID: 17703734. | View |
CJC-1295-ND | National Library of Medicine (NIH) | Growth Hormone | An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma | Timms M, Ganio K, Forbes G, Bailey S, Steel R. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019 Jun;11(6):804-812. doi: 10.1002/dta.2554. Epub 2018 Dec 25. PMID: 30489688. | View |
CJC-1295-ND | National Library of Medicine (NIH) | Enhanced Muscle, Fat Loss, Improved Sleep | Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions | Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016 Jan 2;51(1):73-84. doi: 10.3109/10826084.2015.1082595. Epub 2016 Jan 15. PMID: 26771670. | View |
Epithalon | National Library of Medicine (NIH) | Gene Expression (DNA Regulation) | AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism | Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020 Jan 30;25(3):609. doi: 10.3390/molecules25030609. PMID: 32019204; PMCID: PMC7037223. | View |
Epithalon | National Library of Medicine (NIH) | Cardiovascular, Endocrine, Immune & Nervous Systems | Geroprotective effect of thymalin and epithalamin | Khavinson VKh, Morozov VG. Geroprotektornaia éffektivnost’ timalina i épitalamina [Geroprotective effect of thymalin and epithalamin]. Adv Gerontol. 2002;10:74-84. Russian. PMID: 12577695. | View |
Ipamorelin | National Library of Medicine (NIH) | Bone Mineral Content (Bone Density) | The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats | Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. doi: 10.1677/joe.0.1650569. PMID: 10828840. | View |
Ipamorelin | National Library of Medicine (NIH) | Metabolism | Metabolism of growth hormone releasing peptides | Thomas A, Delahaut P, Krug O, Schänzer W, Thevis M. Metabolism of growth hormone releasing peptides. Anal Chem. 2012 Dec 4;84(23):10252-9. doi: 10.1021/ac302034w. Epub 2012 Nov 13. PMID: 23101768. | View |
Melanotan-MT2 | National Library of Medicine (NIH) | Melanin | Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles | Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM. Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides. 2006 Feb;27(2):388-94. doi: 10.1016/j.peptides.2004.12.038. Epub 2005 Nov 15. PMID: 16293341. | View |
Melanotan-MT2 | National Library of Medicine (NIH) | Appetite and Body Mass | Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction | Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction | View |
Melanotan-MT2 | National Library of Medicine (NIH) | Addiction | Melatonin in drug addiction and addiction management: Exploring an evolving multidimensional relationship | Onaolapo OJ, Onaolapo AY. Melatonin in drug addiction and addiction management: Exploring an evolving multidimensional relationship. World J Psychiatry. 2018 Jun 28;8(2):64-74. doi: 10.5498/wjp.v8.i2.64. PMID: 29988891; PMCID: PMC6033744. | View |
Melanotan-MT2 | National Library of Medicine (NIH) | Erectile Dysfunction (ED) | Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II | Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12 Suppl 4:S74-9. doi: 10.1038/sj.ijir.3900582. PMID: 11035391. | View |
Melanotan-MT2 | National Library of Medicine (NIH) | Binge Drinking (Addiction) | The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice | Olney JJ, Sprow GM, Navarro M, Thiele TE. The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51. doi: 10.1016/j.npep.2013.11.001. Epub 2013 Nov 15. PMID: 24290566; PMCID: PMC3946855. | View |
Melanotan-MT2 | National Library of Medicine (NIH) | Autism | Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder | Lalanne S, Fougerou-Leurent C, Anderson GM, Schroder CM, Nir T, Chokron S, Delorme R, Claustrat B, Bellissant E, Kermarrec S, Franco P, Denis L, Tordjman S. Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder. Int J Mol Sci. 2021 Feb 2;22(3):1490. doi: 10.3390/ijms22031490. PMID: 33540815; PMCID: PMC7867370. | View |
Melanotan-MT2 | National Library of Medicine (NIH) | Sexual Libido | Melatonin enhances sexual behavior in the male rat | Brotto LA, Gorzalka BB. Melatonin enhances sexual behavior in the male rat. Physiol Behav. 2000 Feb;68(4):483-6. doi: 10.1016/s0031-9384(99)00204-8. PMID: 10713287. | View |
Melanotan-MT2 | National Library of Medicine (NIH) | Childhood Autism | Melatonin and Comorbidities in Children with Autism Spectrum Disorder | Gagnon K, Godbout R. Melatonin and Comorbidities in Children with Autism Spectrum Disorder. Curr Dev Disord Rep. 2018;5(3):197-206. doi: 10.1007/s40474-018-0147-0. Epub 2018 Aug 9. PMID: 30148039; PMCID: PMC6096870. | View |
Mots-C | National Library of Medicine (NIH) | Metabolic Stress | Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging | Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023 Jan 20;21(1):36. doi: 10.1186/s12967-023-03885-2. PMID: 36670507; PMCID: PMC9854231. | View |
Mots-C | National Library of Medicine (NIH) | Diabetes (Insulin Resistance) | Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases | Kong BS, Lee C, Cho YM. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. Diabetes Metab J. 2023 May;47(3):315-324. doi: 10.4093/dmj.2022.0333. Epub 2023 Feb 24. PMID: 36824008; PMCID: PMC10244198. | View |
Mots-C | National Library of Medicine (NIH) | Osteoporis | MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway | Hu BT, Chen WZ. MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway. Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7156-7163. doi: 10.26355/eurrev_201811_16247. PMID: 30468456. | View |
Mots-C | National Library of Medicine (NIH) | Mitochondrial Energy | MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation | Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne). 2023 Jan 25;14:1120533. doi: 10.3389/fendo.2023.1120533. PMID: 36761202; PMCID: PMC9905433. | View |
Mots-C | National Library of Medicine (NIH) | Metabolic Disorders, Obesity (Weight Loss) | MOTS-c Functionally Prevents Metabolic Disorders | Gao Y, Wei X, Wei P, Lu H, Zhong L, Tan J, Liu H, Liu Z. MOTS-c Functionally Prevents Metabolic Disorders. Metabolites. 2023 Jan 13;13(1):125. doi: 10.3390/metabo13010125. PMID: 36677050; PMCID: PMC9866798. | View |
Semaglutide | National Library of Medicine (NIH) | Appetite, Weight Loss | Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity | Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017 Sep;19(9):1242-1251. doi: 10.1111/dom.12932. Epub 2017 May 5. PMID: 28266779; PMCID: PMC5573908. | View |
Semaglutide | National Library of Medicine (NIH) | Alzheimer’s Disease | Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer’s disease via the GLP-1R/SIRT1/GLUT4 pathway | Wang ZJ, Li XR, Chai SF, Li WR, Li S, Hou M, Li JL, Ye YC, Cai HY, Hölscher C, Wu MN. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer’s disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. 2023 Dec 1;240:109716. doi: 10.1016/j.neuropharm.2023.109716. Epub 2023 Sep 18. PMID: 37730113. | View |
Semaglutide | National Library of Medicine (NIH) | Alzheimer’s Disease | Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism | Wang Y, Hu H, Liu X, Guo X. Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism. Front Pharmacol. 2023 Feb 23;14:1138499. doi: 10.3389/fphar.2023.1138499. PMID: 36909158; PMCID: PMC9995522. | View |
Semaglutide | National Library of Medicine (NIH) | Insulin Secretion, Diabetes | Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial | Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017 Aug;60(8):1390-1399. doi: 10.1007/s00125-017-4289-0. Epub 2017 May 19. PMID: 28526920; PMCID: PMC5491562. | View |
Tirzepatide | National Library of Medicine (NIH) | Diabetes | Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective | De Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes Obes Metab. 2023 Jan;25(1):3-17. doi: 10.1111/dom.14831. Epub 2022 Aug 31. PMID: 35929488; PMCID: PMC10087310. | View |
Tirzepatide | National Library of Medicine (NIH) | Weight Loss | Weight loss efficiency and safety of tirzepatide: A Systematic review | Lin F, Yu B, Ling B, Lv G, Shang H, Zhao X, Jie X, Chen J, Li Y. Weight loss efficiency and safety of tirzepatide: A Systematic review. PLoS One. 2023 May 4;18(5):e0285197. doi: 10.1371/journal.pone.0285197. PMID: 37141329; PMCID: PMC10159347. | View |
Tirzepatide | National Library of Medicine (NIH) | Digestion | Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials | Cai W, Zhang R, Yao Y, Wu Q, Zhang J. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2024 Jan 31;12:1277113. doi: 10.3389/fpubh.2024.1277113. PMID: 38356942; PMCID: PMC10864442. | View |
Tirzepatide | National Library of Medicine (NIH) | Appetite (Weight Loss) | Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes | Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023 May 1;46(5):998-1004. doi: 10.2337/dc22-1710. PMID: 36857477; PMCID: PMC10154650. | View |
Tirzepatide | National Library of Medicine (NIH) | Diabetes, Insulin Senstivity, Obesity | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review | View |